Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer
ICI-induced colitis had an incidence rate of 3.5% and was associated with the combination of nivolumab and ipilimumab. Most patients with ICI-induced colitis developed mild symptoms that improved with supportive care alone, making ICI therapy resumption possible.
Authors
- Hyun Seok Lee (ORCID: https://orcid.org/0000-0001-9288-0321)
- Eun Soo Kim (ORCID: https://orcid.org/0000-0001-9173-5755)
- Tae Kyun Kim
Institutions
- Kyungpook National University Hospital (KR)
- Kyungpook National University (KR)
Publication Details
- Journal
- The Korean Journal of Internal Medicine
- Published
- 2024-12-31
- DOI
- https://doi.org/10.3904/kjim.2024.135
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70